Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure "ADRIFT"


Phase 2/3 Results N/A

Summary of Purpose

Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 September 2017.

13 Sep 2017 11 Aug 2017 23 Sep 2018 23 Dec 2018 1 Sep 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available